DiCE Molecules Funding & Investors
San Francisco, CA
Founded in 2013, DiCE Molecules develops a transformative platform for the discovery of novel small molecules directed against previously intractable targets in the pharmaceutical industry. Its core technology was invented by Stanford Professor Pehr Harbury, a 2005 recipient of the Macarthur ''genius'' award. In addition to Professor Harbury, the founding team includes Dr. Phil Patten, formerly of Maxygen, Achaogen, and DuPont, who serves as our Chief Scientific Officer; Dr. John Bedbrook, a renowned serial entrepreneur in the agricultural biotechnology space, who is the Chairman of the DiCE Board of Directors; and Dr. Kevin Judice, who served various leadership roles at Genentech, Theravance, and Achaogen prior to joining DiCE as CEO.
dicemolecules.comTotal Amount Raised: $532,381,888
DiCE Molecules Funding Rounds
Post Ipo Equity
$345,000,000
Series C
$60,000,000
Series C Investors
RA Capital ManagementSands Capital ManagementNew Leaf Venture PartnersDeep Track CapitalNorthpond VenturesDriehaus Capital ManagementAsymmetry Capital ManagementOsage University Partners IIHenderson Global InvestorsSoleus CapitalLogos CapitalEventideSeries C
$80,000,000
Series C Investors
RA Capital ManagementNorthpond VenturesOsage University Partners IISanofi-AventisSoleus CapitalDriehaus Capital ManagementAltitude Life Science VenturesAgent CapitalSands Capital ManagementNew Leaf Venture PartnersAlexandria Venture InvestmentsEventideAsymmetry Capital ManagementIPO
Unknown
Series B
$40,481,981
Series B Investors
Northpond VenturesSeries Unknown
$3,999,990
Series Unknown
$2,899,925